43 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
Chung, President and Chief Operating Officer at Sutro. “Sutro’s research innovation represented in STRO-003 illustrates our leadership in ADC design … innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40
8-K
STRO
Sutro Biopharma Inc
15 Jun 20
Regulation FD Disclosure
7:21am
an updated corporate presentation at the Raymond James Human Health Innovation Conference held via virtual format from June 15-18, 2020. A copy
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
–A Pipeline in a Drug (Luvelta, STRO-002)
Luvelta: Exemplifies Sutro’s Innovation in ADC Development Cell-free XpressCF®Proven Technology … and durability of response ADC innovation leader * Based on the estimated value of cash, cash equivalents and marketable securities
8-K
EX-99.1
STRO
Sutro Biopharma Inc
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered
8-K
EX-99.1
yyj4u2
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
1oqfroo7m91 7og
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
DEF 14A
71lt6o2hb6c
26 Apr 19
Definitive proxy
12:00am
DRS/A
k9e 54h77zrep
10 Jul 18
Draft registration statement (amended)
12:00am
DRS
m42ksupltfqq
1 Jun 18
Draft registration statement
12:00am
10-K
rv6vxw52f993t
1 Apr 19
Annual report
12:00am
10-Q
kw121hrjl7 24pgp5f3z
14 Nov 18
Quarterly report
12:00am